Buprenorphine: Therapeutical use in opioid-dependence, depression and schizophrenia;Buprenorphin: Aspekte der therapie von opiatabhangigkeit, depression und schizophrenie

Nervenheilkunde

Volumn 19, Issue 3, 2000, Pages 143-150

  Paetzold, W ^a   Schneider, U ^b   Seifert, J ^b   Eronat, V ^b   Emrich, H M ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

Addiction; Buprenorphine; Depression; Schizophrenia

Indexed keywords

BUPRENORPHINE; ENDORPHIN; OPIATE; OPIATE RECEPTOR;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG DEPENDENCE TREATMENT; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG SPECIFICITY; HUMAN; OPIATE ADDICTION; SCHIZOPHRENIA;

EID: 0034120380     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Amass L, Bickel WK, Higgins ST, Badger GJ. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 1994; 13: 33-45.
2. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994; 64: 1215-28.
3. Amass L, Bickel WK, Crean JP, Blake J, Higgins ST. Alternate-day dosing buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology Berl 1998; 136: 217-25.
4. Angst J, Autenrieth V, Brem F, Koukkou M, Meyer H, Stassen HH, Storck U. Preliminary results of treatment with β-endorphin in depression. In: Endorphins in Mental Health Research. Usdin E, Bunney WE, Kline NS (eds). London: Macmillan 1979; 518-28.
5. Banys P, Ckark HW, Tusel DJ, Sess K, Stewart P, Mongan L, Delucchi K, Callaway E. An open trial of low dose buprenorphine in treating methadone withdrawal. J Subst Abuse Treat 1994; 11: 9-15.
6. Beckett A, Casey A. Analgesics and their antagonists: biochemical aspects and structure activity relationships. Prog Med Chem 1965; 4: 171-218.
7. Bernstein HG, Henning H, Seliger N, Baumann B, Bogerts B. Remarkable β-endorphinergic innervation of human cerebral cortex as revealed by immunohistochemistry. Neuroscience Letters 1996; 215: 33-6.
8. Bernstein HG 1999: Persönliche Mitteilung.
9. Bouchez J, Beuverie P, Touzeau D. Substitution with buprenorphine in methadone-and morphine sulfate-dependent patients. Preliminary results. Eur Addict Res 1998; 4 Suppl. 1: 8-12.
10. Brizer DA, Hartman N, Sweeney J, Millman RB. Effect of methadone plus neuroleptics on treatment-resistent chronic paranoid schizophrenie. Am J Psychiatry 1985; 142: 1106-7.
11. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the κ-opioid receptor. Science 1981; 215: 413-5.
12. Chawarski MC, Schottenfeld RS, O'Connor PG, Pakes J. Plasma concentration of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend 1999; 55: 157-63.
13. Comfort A. Morphin as an antipsychotic. Relevance of a 19th century therapeutic fashion. Lancet 1977; 2: 448-9.
14. Corbett AD, Paterson SJ, McKnight AT, Magnan J, Kosterlitz HW. Dynorphin 1-8 and Dynorphin 1-9 are ligands for the κ-subtype of opioid receptors. Nature 1982; 299: 79-81.
15. Cowan A. Evaluation in nonhuman primates: Evaluation of the physical dependence capacities of oripavine-thebaine partial agonists in patas monkeys. In: Narcotic Antagonists. Braude MC, Harris LS, May EL, Smith JP, Villarreal JE (Hrsg). New York: Raven Press 1974; 427-38.
16. Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977; 60: 537-45.
17. Diamant K, Fischer G, Schneider C, Lenzinger E, Pezawas L, Schindler S, Eder H. Outpatient opiate detoxification treatment with buprenorphine. Preliminary investigation. Eur Addict Res 1998; 4: 198-202.
18. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatric Research 1987; 22: 303-10.
19. Dum J, Bläsig J, Herz A. Buprenorphine: demonstration of physical dependence liability. Eur J Pharmacol 1981; 70: 293-300.
20. Eder H, Fischer G, Gombas W, Jagsch R, Stuhlinger G, Kasper S. Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur Addict Res 1998; 4 Suppl. 1: 3-7.
21. Emrich HM, Cording C, Pirée S, Kölling A, Zerssen v D, Herz A. Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmacopsychiat 1997; 10: 265-70.
22. Emrich HM, Höllt V, Kissling W, Fischler M, Laspe H, Heinemann H, von Zerssen D, Herz A. Beta-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatrie disorders. Pharmakopsychiatr Neuro-Psychopharmakol 1979; 12: 269.
23. Emrich HM, Vogt P, Herz A. A possible role of opioids in depression: Significant improvement after buprenorphine. In: Biological Psychiatry 1981. Perris C, Struwe G, Jansson B (Hrsg.). Amsterdam: Elsevier/ North-Holland 1981; 380-5.
24. Emrich HM. A possible role of opioid substances in depression. In: Typical and Atypical antidepressants, Voll, Molecular Mechanisms. Costa E, Racagni G (Hrsg.). New York: Raven Press 1982; 77-84.
25. Emrich HM, Vogt P, Herz A. Possible antidepressive effects on opioids: Action of buprenorphine. Ann NY Acad Sci 1982; 398: 108-12.
26. Emrich HM. Possible Role of Opioids in Mental Disorders. Present State of Knowledge. In: Psychoneuroendocrine Dysfunction, Nandkumar SS, Alexander GD (Hrsg.) New York, London: Plenum Medical Book Company 1984; 293-307.
27. Fink M, Simeon J, Itil TM, Freedman AH. Clinical antidepressant activity of cyclazocine - A narcotic antagonist. Clin Pharmacol Ther 1970; 11: 41-8.
28. Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47: 525-34.
29. Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998; 50: 1-8.
30. Gerner RH, Catlin DH, Gorelick DA, Hui KK, Li CH. β-Endorphin: Intravenous infusion causes behavioural change in psychiatric inpatients. Arch Gen Psychiatry 1980; 37: 642-7.
31. Groves S, Nutt DJ. Buprenorphine and Schizophrenia. Hum Psychopharmacol 1991; 6: 71-2.
32. Harcus AH, Ward AE, Smith DW. Buprenorphin in post-operative pain: Results in 7500 patients. Anaesthesia 1980; 35: 382-6.
33. Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979; 17: 81-110.
34. Holladay JW, Tortella FC, Belenky GL. Electroconvulsive shock (ECS) results in a functional activation of endorphin systems. In: The Role of Endorphins in Neuropsychiatry. Emrich HM (Hrsg.). Basel: Karger 1981; 142-57.
35. Jaffe JH, Martin WR. Opiod analgesics and antagonists. In: The Pharmacological Basis of Therapeutics. Gilman AG, Rall TW, Nies AS, Taylor P (Hrsg.) New York: Pergamon 1990; 485-521.
36. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 1978; 35: 501-16.
37. Johnson RE, Cone EJ, Henningfield JE, Fudala PJ. Use of buprenorphine in the treatment of opiate addiction. I. Physiological and behavioral effects during a rapid dose induction. Clin Pharmacol Ther 1989; 46: 335-43.
38. Joyce EM, Iversen SD. The effect of morphine applied locally to mesencephalic dopamine cell bodies on spontaneous motor activity in the rat. Neurosci Lett 1979; 14: 207-12.
39. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142: 1259-64.
40. Kosten TR, Kleber HD. Buprenorphin detoxification from opioid dependence: a pilot study. Life Sci 1988; 42: 635-41.
41. Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD. Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend 1990; 25: 73-8.
42. Kosten TR, Morgan C, Kosten TA. Depressive symptoms during buprenoprhine treatment of opioid abusers. J Substance abuse treat 1990; 7: 514.
43. Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 1991; 17: 119-28.
44. Kraepelin E. Einführung in die Psychiatrische Klinik. Leipzig: Joh. Ambrosius Barth-Verlag 1901; 11.
45. Krausz M, Verthein U, Degkwitz P. Prävalenz psychischer Störungen bei Opiatabhängigen mit Kontakt zum Drogenhilfssystem. Nervenarzt 1998; 69: 557-67.
46. Kuhlman JJ, Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenoprhine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93: 549-59.
47. Leander JD. Buprenorphine has potent κ opioid receptor antagonist activity. Neuropsychopharmacology 1987; 26: 1445-7.
48. Lewis JW. Ring C-bridged derivatives of thebaine and oripavine. In: Narcotic Antagonists. Braude MC, Harris LS, May EL, Smith JP, Villarreal JE (Hrsg.) New York: Raven Press 1974; 123-36.
49. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53: 401-7.
50. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93: 475-86.
51. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine and nalorphine-like drugs in nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-32.
52. Mattick RP, Hall W (1996) Are detoxification programmes effective? Lancet 1996; 347: 97-100.
53. McCarthy PS, Howlett GJ. Physical dependence included by opiate partial agonists in the rat. Neuropeptides 1984; 5: 233-47.
54. McDiarmid J. The hypodermic injection of morphia in insanity. J Med Sci 1876; 22: 18-42.
55. Mello NK, Mendelson JH. Buprenorphine supresses heroin use by heroin addicts. Science 1980; 207: 657-9.
56. Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology Berl 1999; 141: 37-46.
57. Moatti JP, Souville M, Escaffre N, Obadia Y. French general practitioners' attitudes toward maintenance drug abuse treatment with buprenorphine. Addiction 1998; 93: 1567-75.
58. Mongan L, Callaway E. Buprenorphine responders. Biol Psychiatry 1990; 28: 1065-80.
59. Nigam AK, Srivastava RP, Saxena S, Chavan BS, Sundaram KR. Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction 1994; 89: 317-20.
60. Nutt D, Groves S, Coupland N, Glue P. Buprenorphine in Psychiatric Disorders. In: Buprenorphine. Combatting drug abuse with a unique opiod. Cowan A, Lewis JW (Hrsg.). Wiley-Liss 1995; 175-86.
61. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med 1997; 127: 526-30.
62. Paetzold W, Schneider U, Eronat V, Holze I, Seifert J, Emrich HM. Buprenorphin und Carbamazepin in der Entgiftungsbehandlung von Opiatabhängigen mit Drogenbeigebrauch. In: Entwicklungen in der Suchtmedizin. (Schriftenreihe der DGDS e.V., Band 2). Zerdick J (Hrsg.). Berlin: VWB - Verlag für Wissenschaft und Bildung 1999; 297-314.
63. Paetzold W, Schneider U, Eronat V, Seifert J, Holze I, Emrich HM. Detoxifikation polytoxikomaner Patienten mit Buprenorphin: Auswirkungen auf die Entzugssymptomatik. (zur Veröffentlichung eingereicht).
64. Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by κ opiat receptors. Science 1986; 233: 774-6.
65. Poser W, Poser S. Medikamente - Mißbrauch und Abhängigkeit. New York: Thieme Verlag 1996; 58-87.
66. Pickar D, Vartanian F, Bunney W, Maier HP, Gastpar MT, Prakash R, Sethi BB, Lideman R, Belyaev BS, Tsutsukolkovskaja MVA, Jungkunz G, Nedopil M, Verhoeven W, van Praag H. Short-term naloxone administration in schizophrenic and manic patients. Arch Gen Psychiatry 1982; 39: 313-9.
67. Schmauss C, Yassourides A, Emrich HM. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry 1987; 144: 1340-2.
68. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54: 713-20.
69. Senay EC. Methadone maintenance treatment. Int J Addict 1985; 20: 803-21.
70. Seow SS, Quingley AJ, Ilett KF, Dusci LJ, Swensen G, Harrison-Stewwart A, Rappeport L. Buprenorphine a new maintenance opiate? Med J Aust 1986; 144: 407-11.
71. Spanagel R, Herz A, Shippenberg TS. The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study. Neurochem 1990; 55: 1734-40.
72. Terenius L, Wahlstrom A, Lindstrom L, Widerlov E. Increased CSF levels of endorphins in chronic psychosis. Neurosci Lett 1976; 3: 157-62.
73. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998; 22: 430-4.
74. Uehlinger C, Deglon J, Livoti S, Petitjean S, Waldvogel D, Ladewig D. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study. Eur Addict Res 1998; 4 Suppl. 1: 13-8.
75. Walsh SL, June HL, Schuh KJ, Preston KL, Bigelwo GE, Stitzer ML. Effects of buprenorphine and methadone in methadone maintained subjects. Psychopharmacology Berl 1995; 119: 268-76.
76. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999; 353: 221-6.
77. Wolf K. Steady-State Pharmacocinetics of Methadone in Opioid Addicts. Clin Pharmacol 1993; 44: 189.
78. Woods JH, Gmerek DE. Substitution and primary dependence studies in animals. Drug Alcohol Depend 1985; 14: 233-47.
79. Woody GE, O'Brien CP, Rickels K. Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. Am J Psychiatry 1975; 132: 447-50.
80. Yanagita T. Self administration studies on psychological dependence. Trends Pharmacol Sci 1980; 1: 161-4.